APA (7th ed.) Citation

S, L., J, R., H, Q., A, H., I, K., W, J., . . . A, S. (2024). Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21. British journal of haematology, 205(3), 900. https://doi.org/10.1111/bjh.19578

Chicago Style (17th ed.) Citation

S, Lim, Reynolds J, Quach H, Hutchinson A, Kerridge I, Janowski W, Bergin K, and Spencer A. "Response Adaptive Salvage Treatment with Daratumumab-lenalidomide-dexamethasone for Newly Diagnosed Transplant-eligible Multiple Myeloma Patients Failing Front-line Bortezomib-based Induction Therapy-ALLG MM21." British Journal of Haematology 205, no. 3 (2024): 900. https://doi.org/10.1111/bjh.19578.

MLA (9th ed.) Citation

S, Lim, et al. "Response Adaptive Salvage Treatment with Daratumumab-lenalidomide-dexamethasone for Newly Diagnosed Transplant-eligible Multiple Myeloma Patients Failing Front-line Bortezomib-based Induction Therapy-ALLG MM21." British Journal of Haematology, vol. 205, no. 3, 2024, p. 900, https://doi.org/10.1111/bjh.19578.